# Phase 2 Hodgkin Disease trials recruiting: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 2 for Hodgkin Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Hodgkin Disease trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/hodgkin-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| April 27, 2026 | NCT07551583 | Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Hodgkin Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551583) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| November 18, 2025 | NCT07234487 | Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Hodgkin Lymphoma | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234487) |
| October 6, 2025 | NCT07209059 | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | National Research Center for Hematology, Russia | Phase 2 | Recruiting | Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209059) |
| September 10, 2025 | NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Large B-cell Lymphoma, Hodgkin Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07164469) |
| June 15, 2025 | NCT07021989 | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07021989) |
| June 3, 2025 | NCT07002216 | BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma | University of Miami | Phase 2 | Recruiting | Hodgkin Lymphoma, Advanced Hodgkin Lymphoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07002216) |
| May 22, 2025 | NCT06984146 | Nivo40-AVD for Advanced Classic Hodgkin Lymphoma | National Medical Research Radiological Centre of the Ministry of Health of Russia | Phase 2 | Recruiting | Hodgkin Lymphoma, Adult | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984146) |
| April 9, 2025 | NCT06919679 | Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma | University of Cologne | Phase 2 | Not yet recruiting | Hodgkin Lymphoma (Category) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06919679) |
| April 8, 2025 | NCT06915246 | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | VIVUS LLC | Phase 2 | Recruiting | Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06915246) |
| February 6, 2025 | NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Hodgkin Lymphoma | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06812858) |
| August 30, 2024 | NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580002) |
| April 22, 2024 | NCT06377566 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Hodgkin Lymphoma | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06377566) |
| September 28, 2023 | NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1... | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06059391) |
| September 21, 2023 | NCT06045195 | Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma | University of Cologne | Phase 2 | Not yet recruiting | Hodgkin Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045195) |
| August 4, 2023 | NCT05977673 | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy | Fondazione Italiana Linfomi - ETS | Phase 2 | Recruiting | Hodgkin Lymphoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05977673) |
| April 5, 2023 | NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | University of Florida | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05800210) |
| November 25, 2022 | NCT05627115 | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma | University College, London | Phase 2 | Not yet recruiting | Hodgkin Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05627115) |
| November 14, 2022 | NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05615636) |
| May 2, 2022 | NCT05355051 | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Hodgkin's Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05355051) |
| February 23, 2022 | NCT05253495 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | New York Medical College | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Hodgkin Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05253495) |
| January 6, 2022 | NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | Canadian Cancer Trials Group | Phase 2 | Recruiting | Hodgkin Lymphoma | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05180097) |
| June 23, 2021 | NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | University Hospital, Clermont-Ferrand | Phase 2 | Recruiting | Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04935684) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 5 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Mayo Clinic | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| Fred Hutchinson Cancer Center | 2 |
| City of Hope Medical Center | 2 |
| University of Cologne | 2 |
| University College, London | 1 |
| National Research Center for Hematology, Russia | 1 |
| University of Birmingham | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| University of Miami | 1 |
| Canadian Cancer Trials Group | 1 |
| University of California, Irvine | 1 |
| University of Florida | 1 |
| National Medical Research Radiological Centre of the Ministry of Health of Russia | 1 |
| New York Medical College | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| University of Liege | 1 |
| [VIVUS LLC](https://specstream.ai/data/clinical-trials/company/vivus-llc) | 1 |
| Fondazione Italiana Linfomi - ETS | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| Russia | 4 |
| Kazakhstan | 1 |
| United Kingdom | 1 |
| Australia | 1 |
| Canada | 1 |
| France | 1 |
| Uganda | 1 |
| Belgium | 1 |
| Italy | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
